Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nyse  >  Pfizer    PFE

My previous session
Most popular
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Pfizer : Value of Rheumatoid Arthritis Treatment

share with twitter share with LinkedIn share with facebook
share via e-mail
11/08/2018 | 04:14am EST

Rheumatoid arthritis (RA) is a chronic, systemic (potentially affects your whole body) inflammatory disorder that typically affects the small joints in your hands and feet. It is an autoimmune disease, where a person's immune system attacks joint tissues and potentially other body parts/organs for unknown reasons.1 As a result, RA causes pain, inflammation, and eventually joint damage and malformation.2 Rheumatoid arthritis can cause people to feel sick, tired, and feverish; it also affects joints symmetrically, where joint pain is felt on both sides of the body.2 RA differs greatly from osteoarthritis (OA), which is a degenerative joint disease that only affects joint function.2

RA affects more than 17.6 million people worldwide, with more than 1.6 million people in the United States and 6.2 million people in Europe.3, 4, 5 Rheumatoid arthritis can occur at any age. In fact, approximately 294,000 children under the age of 18 in the U.S. were affected by pediatric arthritis and rheumatologic conditions based on data between 2001-2004.6 However, arthritis usually occurs after age 40, and it is much more common in women than in men. As expected, the study also showed that the incidence of RA rose with age, and peaked among people aged 65-74 years (all estimates were age-adjusted to 2000 U.S. population). Additionally, over the past half century, many studies have found mortality to be increased in patients with established RA in comparison with the general population.7

Health Burden of RA

Generally speaking, people with RA have worse functional status than those with osteoarthritis.8 RA patients have been reported to experience more losses in function than people without arthritis in every domain of human activity including work, leisure and social relations.8 Work loss among people with RA is the highest among service workers than among those in jobs with few physical demands.9

One study examining self-reported quality of life found that compared to those without arthritis, RA patients were 40% more likely to report poor or fair general health, 30% more likely to need help with personal care, and twice as likely to have a health-related activity limitation.8

RA is associated with common co-morbidities, including following:

  • Cardiovascular disease (CVD), in particular ischemic heart disease, is more common among people with RA.10 The Rochester Epidemiology Project study found that people with RA were more likely to have hospitalizations because of myocardial infarction (MI) prior to diagnosis.10 People with RA have greater evidence of subclinical atherosclerotic disease,11 and risk of silent MI.12 It is unknown whether the increase in CVD mortality is due to the disease, the risk factor profile of RA (e.g., presence of hypertension, more likely to be smokers), or the effects of the drugs used to treat the condition.11
  • Infections are another important and primary cause of death among people with RA and may be responsible for one-quarter of deaths among people with RA.13 It is unclear whether this increased susceptibility arising from immunosuppression is due to the intrinsic immune dysfunction in people with RA, the effects of the drugs used to treat it, or both. 12
  • Mental health conditions: The high prevalence of anxiety and depression has been documented in several clinical populations of RA patients.14, 15 Both conditions are associated with increased disease activity and decreased physical function.8 Psychosocial factors have been identified as additional burdens on RA patients. Arthritis may require people to cope with pain, stiffness, fatigue, physical limitations, and in severe cases, physical deformities; managing these aspects of the illness influences people's ability to engage in meaningful, obligatory and discretionary activities, including the domains of work, family life, leisure, and social relationships.16 Symptoms from arthritis can threaten the ability to participate in many life activities, and this may compromise psychological and social well-being.

In one large study researchers concluded that RA carries a risk of mortality that is approximately 38% greater than for the general population. The risk was even greater for women; with a 55% increased risk compared to women of the general population.17

Economic Impact of RA
  • In the U.K., the National Audit Office (NAO) estimates that rheumatoid arthritis costs the National Health Service (NHS) around £560 million a year in health care costs ($829 million in 2009 U.S. dollars), with the majority of this in the acute sector, and that the additional cost to the economy of sick leave and work-related disability is £1.8 billion a year ($2.67 billion in 2009 U.S. dollars).18
  • Results from a 2011 U.K. study indicate that an increase in earlier treatment for RA patients could produce significant benefits in terms of productivity, with gains of £31 million ($46 million in 2009 U.S. dollars) for the economy due to reduced sick leave and lost employment. According to the U.K.'s NAO, 10% of patients with RA are treated within 3 months of symptom onset; its economic modeling suggests that increasing this to 20% would initially cause costs to the NHS to rise, but earlier treatment could become cost-neutral after nearly 9 years.19
  • Employee burden: One U.S. study in 2010 found that the annual out-of-pocket costs of the employed population were $1,193 for patients with RA, with annual excess out-of-pocket costs of $510 per privately insured patient.19
  • In the same study, the annual total costs for the privately insured and the Medicare populations were estimated to be $306 million and $600 million, respectively. Excess per-patient costs for uninsured RA patients were estimated to be $5,758, which, when weighted by the uninsured prevalence, aggregates to an annual total cost of $560 million.20

Birnbaum H, Pike C, Kaufman R, Marynchenko M, Kidolezi Y. Societal cost of rheumatoid arthritis patients in the US. Curr Med Res Opin. 2010; 26:77-90. Cardarelli WJ. Implications for managed care and specialty pharmacy in rheumatoid arthritis. Am J Manag Care. 2012; 18(suppl 13):S315-S324.
Medication Adherence and RA
  • A 2012 study that investigated the impact of RA treatment shows medication adherence early on in treatment may reduce the costs associated with missed work and lost productivity resulting from an incidence of short-term disability.20
  • Researchers also found that high cost sharing for RA medicines decreased patient adherence and increased incidence and longer duration of short-term disability leave. It is estimated that when employees with RA take their medication as directed, their lost productivity drops by 26 percent.21
  • An Integrated Benefits Institute study of 17 employer groups found that if all 5,483 employees with RA who were previously non-adherent to RA medicines began to fill their prescriptions at the same rate as those who did adhere, their employers would save $4.4 million in lost productivity costs ($3.2 million from reduced short-term disability incidence, and another $1.2 million from declining disability duration).22
Evolving Pharmaceutical Treatment Options and Strategies in RA

Over the last several decades, research in several areas important to RA has greatly increased our understanding of the immune system, genetics, and biology and, as a result, scientists are now able to treat RA in new ways that were not possible in the past.1 Historically, treatment for RA started with corticosteroids/nonsteroida antiinflammatory drugs (NSAIDs), then slowly progressed to non-biologic (small molecule) disease-modifying anti-rheumatic drugs (DMARDs) and finally to biologic DMARDs.23

Treatment guidelines have changed with the increasing array of biologic DMARDs available. Today, a more aggressive treatment approach is recommended than in the past; with non-biologic DMARDs initiated within three months of diagnosis to reduce disease activity and prevent joint deformity.25 In 2008, the American College of Rheumatology updated RA medical management guidelines;25 describing which biologic DMARDs are indicated for specific RA disease profiles (e.g., features such as disease activity, signs and symptoms, and prognosis). These guidelines also recommend that treatment with non-biologic and biologic therapies should be accompanied by non-medical interventions including physical and occupational therapy and antiinflammatory pharmacologic interventions (e.g., treatment with NSAIDs, intraarticular and oral glucocorticoids).25

Treatment paradigms in RA management continue to evolve, and those changes have been attributed to a number of factors, including the effectiveness of novel DMARDs and biologic agents.24 In 2010, another set of guidelines addressed the principles of "treating to target" in RA. These guidelines contain 4 overarching principles that form the basis of this treat-to-target paradigm. These principles stress the importance of shared decision making between patient and rheumatologist; maximizing long-term health related quality of life; reducing inflammation; and measuring disease activity and adjusting therapy accordingly to optimize outcomes. There are numerous RA activity measuring tools available in clinical practice today, each designed to monitor disease activity to achieve the best possible outcome for patients; helping rheumatologists to treat-to-target.

Benefits of Improved Treatments

Today, patients with RA generally experience greater healthrelated quality of life than those diagnosed with the disease 20 years ago. According to one study spanning from 1990 to 2011, results showed a significant reduction in patients who experienced depressed mood, anxiety, and physical disability.25 Researchers attribute new treatment strategies shown in clinical trials to lower levels of disease activity, improvement in psychological well-being, and physical functionality. In some recent clinical trials, work disability has been included as an outcome measure. Intensive combination DMARDs and biologic therapies have been associated with beneficial effects on this measure. One study showed that disease remission can be achieved using traditional DMARDs, and in those patients who achieved remission within 6 months, none were work disabled at 5 years.26 The number of newly diagnosed RA patients who are disabled after the first four years of treatment has been reduced by half compared to 20 years ago. These positive developments have been attributed to increased availability of improved treatment options and treatment strategies.27

As RA treatment strategies improved from the late 1990s to the early 2000s, some physicians began to measure changes in RA symptoms by using criteria called the American College of Rheumatology (ACR) score. The ACR score was initially limited to measuring a maximum of 20 percent improvement but, by 2007, it was increased to include 50 percent and 70 percent improvement (ACR 50 and ACR 70) due to the initial threshold being too low. This shift reflected the gains made in RA treatment attributed to new and improved therapeutic agents and their role in combination therapy.27

RA treatment methods have significantly evolved from targeting RA symptoms to reducing disease activity. Research and development efforts have effectively reduced the burden of RA and its socioeconomic impact by redefining and advancing care. Still, unmet medical need exists, and some patients fail to meet their treatment goals.28 As research and development continues to evolve and newer therapies are made available, we can look forward to addressing the needs of more RA patients, and the positive effects they have to the individual and to society.

Patient Perspectives

Elizabeth Shepley, a mother of two from Shillington, PA was just 25 years old when she was diagnosed. After about 3 years, she decided to get help.

"It may be out of my control that I have RA, but it is within my control to treat it… and to function, as I deserve to function - Elizabeth Shepley"

1 National Institute of Arthritis and Musculoskeletal and Skin Diseases, (NIAMS). (2013). Handout on Health: Rheumatoid Arthritis. Accessed April 10, 2014 at http://www.niams. nih.gov/health_info/Rheumatic_Disease/default.asp(link is external)
2 National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). (2013). Handout on Health: Osteoarthritis. Accessed April 10, 2014 at http://www.niams.nih.gov/ Health_info/Osteoarthritis/default.asp(link is external)
3 Annals of Rheumatic Diseases, "The global burden of rheumatoid arthritis: estimates from the Global Burden of Disease 2010 study." Accessed 14 July 2015. Available at http:// ard.bmj.com/content/early/2014/02/18/annrheumdis-2013-204627(link is external)
4 Sacks J, Lou Y, Helmick C. Prevalence of Specific Types of Arthritis and Other Rheumatic Conditions in the Ambulatory Health Care System in the United States 2001-2005. Arthritis Care and Research. 2010. 62(4): 460-464
5 Howden, L, Meyer, J. 2010 U.S. Census Bureau results - U.S. Census Bureau, 2010 Census Summary File 1
6 Sacks, J., Helmick, C., Yao-Hua L., Ilowite N., & Bowyer S. (2007). Prevalence of and Annual ambulatory Health Care Visits for Pediatric Arthritis and Other Rheumatologic Conditions in the US in 2001-2004. Arthritis Rheum, vol. 57, 1439-1445
7 Meune, C., Touzé, E., Trinquart, L., & Allanore, Y. (2009). Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systematic review and metaanalysis of cohort studies. Rheumatology (Oxford), 48(10):1309-13. doi: 10.1093/rheumatology/kep252
8 Centers for Disease Control and Prevention (CDC). 2012. "Rheumatoid Arthritis, Impact on health-related quality of life (HRQOL)". Accessed on May 5, 2014 at http://www.cdc. gov/arthritis/basics/rheumatoid.htm(link is external)
9 Yelin, E., Henke, C., & Epstein, W. (1987). The work dynamics of the person with rheumatoid arthritis. Arthritis Rheum., 30(5):507-12
10Symmons, D.P., & Gabriel, S.E. (2011). Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE. Nat Rev Rheumatol., 7(7):399-408
11 Wasko, M.C. (2004). Comorbid conditions in patients with rheumatic diseases: an update. CurrOpinRheumato, 16(2):109-13
12 Boonen, A.,& Severens, J.L. (2011). The burden of illness of rheumatoid arthritis. Clin Rheumatol, 30,Suppl 1:S3-8
13 Mikuls, T.R., & Saag, K.G. (2001). Comorbidity in rheumatoid arthritis. RheumDisClinNorth Am, 27(2):283-303
14 Dickens, C., McGowan, L., Clark-Carter, D., & Creed, F. (2002). Depression in rheumatoid arthritis: a systematic review of the literature with meta-analysis. Psychosom Med, 64(1):52-60
15 Soderlin, M.K., Hakala, M., & Nieminen, P. (2000). Anxiety and depression in a community-based rheumatoid arthritis population. Scandinavian Journal of Rheumatology, 29(3):177-83
16 Katz, P.P., Morris, A., & Yelin, E. (2006). Prevalence and predictors of disability in valued life activities among individuals with rheumatoid arthritis. Ann Rheum Dis, 65:763-769
17 Gabriel, S.E., Crowson, C.D., & O'Fallon, W.M. (1999). Mortality in rheumatoid arthritis: have we made an impact in 4 decades? J Rheumatol, 26(12):2529-34
18 Zhang, W. & Anis, A.H. (2011). The economic burden of rheumatoid arthritis: beyond health care costs. Clin Rheumatol, 30 (Suppl 1): S25-S32)
19 Birnbaum, H., Pike, C., Kaufman, R., Marynchenko, M., Kidolezi, Y., & Cifaldi, M. (2010). Societal cost of rheumatoid arthritis patients in the US. Current Medical Research & Opinion, 26 (1):77-90
20 Jinnett, K. & Parry, T. (24 May 2012). Valuing Lost Work Time: Connecting Medication Adherence and Short-Term Disability. AJMC.com. Accessed on May 5, 2014 at http://www. ajmc.com/publications/ajpb/2012/ajpb_mayjun2012/valuing-lost-work-time-connecting-medication-adherence-and-short-term-disability/1(link is external)
21 Pharmaceutical Research and Manufacturers of America (PhRMA). The Biopharmaceutical Industry Helps Strengthen the U.S. Economy. Accessed on May 4, 2014 at http://www.phrma.org/economic-impact(link is external)
23 Saag, K.G., et al. (2008). American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis and rheumatism, 59(6):762-84
24 Ruderman, E.M., Kamala, M.N., Ferrell, S., Sapir, T., & Cameron, D.R. (2012). Incorporating the Treat-to-Target Concept in Rheumatoid Arthritis. Journal of Managed Care Pharmacy, Supp. Vol. 18 No. 9-a
25 Overman, C.L., Jurgens, M.S., Bossema, E.R., Jacobs, J.W., Bijlsma, J.W., & Geenen, R. (16 Jul 2013). Patient with rheumatoid arthritis nowadays are less psychologically distressed and physically disabled than patients two decades ago. Arthritis Care & Research. American College of Rheumatology
26 E. Nikiphorou, et al. (2012) Work disability rates in RA. Results from an inception cohort with 23 years follow-up. Rheumatology 2012;51:385-392 doi:10.1093/rheumatology/ ker401
27 Augustyn, C., Walker, B., & Goss, T.F. (March 2013). Recognizing the Value of Innovation in the Treatment of Rheumatoid Arthritis. White Paper. PhRMA. Accessed on May 4, 2014 at http://www.phrma.org/sites/default/files/pdf/rawhitepaperfinal2.pdf(link is external)
28 Campbell, J., Lowe, D., & Slleman, M.A. (2010). Developing the next generation of monoclonal antibodies for the treatment of rheumatoid arthritis. British Journal of Pharmacology, 162:1470-1484. doi: 10.1111/j.1476-5381/2010/01183.x

Issued by Global Policy and International Public Affairs


Pfizer Inc. published this content on 07 November 2018 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 08 November 2018 09:13:08 UTC

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on PFIZER
11:06aEXCLUSIVE : Private equity firms circling Nestle's skin health business - source..
05:43aGlaxoSmithKline Chairman Philip Hampton to Step Down -- Update
03:16aPHILIP HAMPTON : GSK Chairman Hampton to step down ahead of split
03:12aGSK Chairman Hampton to step down ahead of split
01/19PFIZER : cuts five biosimilar candidates and 150 jobs in R&D shakeup
01/19JOHNSON & JOHNSON : J&Js Erleada cleared for early prostate cancer in Europe
01/19PFIZER : inks collaboration deal to use CytoReason`s cell-centered models of imm..
01/18Samsung Bioepis biosimilar to Roche's Herceptin wins FDA nod
01/18PFIZER : Pakistan Limited and Pakistan Bait-ul-Mal, Government of Pakistan signs..
01/18PFIZER : signs deal to support cancer patients' treatment
More news
Financials ($)
Sales 2018 53 608 M
EBIT 2018 20 023 M
Net income 2018 13 632 M
Debt 2018 28 504 M
Yield 2018 3,22%
P/E ratio 2018 18,04
P/E ratio 2019 17,13
EV / Sales 2018 5,13x
EV / Sales 2019 5,05x
Capitalization 247 B
Duration : Period :
Pfizer Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 14
Average target price 45,3 $
Spread / Average Target 6,6%
EPS Revisions
Albert Bourla Director, Chief Executive & Operating Officer
Ian C. Read Executive Chairman
Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
Freda C. Lewis-Hall Chief Medical Officer & Executive Vice President
W. Don Cornwell Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER-2.57%246 674
JOHNSON & JOHNSON1.27%350 508
NOVARTIS5.66%227 840
ROCHE HOLDING LTD.6.16%223 498
MERCK AND COMPANY-0.71%197 291
AMGEN4.73%129 916